221 related articles for article (PubMed ID: 28436256)
21. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
[TBL] [Abstract][Full Text] [Related]
22. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis.
Deschaseaux C; McSharry M; Hudson E; Agrawal R; Turner SJ
J Manag Care Spec Pharm; 2016 May; 22(5):561-71. PubMed ID: 27123917
[TBL] [Abstract][Full Text] [Related]
23. Healthcare resource utilisation and cost associated with elevated potassium levels: a Danish population-based cohort study.
Kim K; Thomsen RW; Nicolaisen SK; Hasvold LP; Palaka E; Sørensen HT
BMJ Open; 2019 Apr; 9(4):e026465. PubMed ID: 30940761
[TBL] [Abstract][Full Text] [Related]
24. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
[TBL] [Abstract][Full Text] [Related]
25. Associations between serum potassium and adverse clinical outcomes: A systematic literature review.
Palaka E; Grandy S; Darlington O; McEwan P; van Doornewaard A
Int J Clin Pract; 2020 Jan; 74(1):e13421. PubMed ID: 31532067
[TBL] [Abstract][Full Text] [Related]
26. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
Dwyer JP; Agiro A; Desai P; Oluwatosin Y
Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
[TBL] [Abstract][Full Text] [Related]
27. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.
Pitt B; Garza D
Expert Opin Drug Saf; 2018 May; 17(5):525-535. PubMed ID: 29667438
[TBL] [Abstract][Full Text] [Related]
28. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.
Bakhai A; Palaka E; Linde C; Bennett H; Furuland H; Qin L; McEwan P; Evans M
J Med Econ; 2018 Dec; 21(12):1172-1182. PubMed ID: 30160541
[TBL] [Abstract][Full Text] [Related]
29. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.
Pecoits-Filho R; Fliser D; Tu C; Zee J; Bieber B; Wong MMY; Port F; Combe C; Lopes AA; Reichel H; Narita I; Stengel B; Robinson BM; Massy Z;
J Clin Hypertens (Greenwich); 2019 Jul; 21(7):991-1001. PubMed ID: 31169352
[TBL] [Abstract][Full Text] [Related]
30. [Hyperkalemia in heart failure: etiology, epidemiology and prognosis].
Romani S; Sinagra G
G Ital Cardiol (Rome); 2021 Dec; 22(12 Suppl 1):e3-e7. PubMed ID: 34935773
[TBL] [Abstract][Full Text] [Related]
31. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.
Thomsen RW; Nicolaisen SK; Hasvold P; Sanchez RG; Pedersen L; Adelborg K; Egstrup K; Egfjord M; Sørensen HT
Nephrol Dial Transplant; 2018 Sep; 33(9):1610-1620. PubMed ID: 29177463
[TBL] [Abstract][Full Text] [Related]
32. All-cause costs increase exponentially with increased chronic kidney disease stage.
Golestaneh L; Alvarez PJ; Reaven NL; Funk SE; McGaughey KJ; Romero A; Brenner MS; Onuigbo M
Am J Manag Care; 2017 Jun; 23(10 Suppl):S163-S172. PubMed ID: 28978205
[TBL] [Abstract][Full Text] [Related]
33. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
Desai NR; Rowan CG; Alvarez PJ; Fogli J; Toto RD
PLoS One; 2020; 15(1):e0226844. PubMed ID: 31910208
[TBL] [Abstract][Full Text] [Related]
34. Hyperkalemia in the Hypertensive Patient.
Lakkis JI; Weir MR
Curr Cardiol Rep; 2018 Mar; 20(2):12. PubMed ID: 29492706
[TBL] [Abstract][Full Text] [Related]
35. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
[TBL] [Abstract][Full Text] [Related]
36. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
[TBL] [Abstract][Full Text] [Related]
37. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
[No Abstract] [Full Text] [Related]
38. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
39. Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population.
Muhlestein JB; Kammerer J; Bair TL; Knowlton KU; Le VT; Anderson JL; Lappé DL; May HT
ESC Heart Fail; 2021 Feb; 8(1):691-696. PubMed ID: 33331114
[TBL] [Abstract][Full Text] [Related]
40. Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study.
Stawowczyk E; Ward T; Paoletti E; Senni M; de Arellano AR
Cost Eff Resour Alloc; 2024 May; 22(1):42. PubMed ID: 38769560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
